In the CRC liver metastasis model, anti-FGL1 mAb–treated mice showed significantly prolonged survival after 4 treatments, with a median survival time ranging from 36 ± 1.37 days to 46 ± 1.60 days (Figure 6G). Here, FGL1 is linked to colorectal carcinoma.